Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Post-transfusional iron overload in the haemoglobinopathies.

Thuret I.

C R Biol. 2013 Mar;336(3):164-72. doi: 10.1016/j.crvi.2012.09.010. Epub 2012 Oct 24. Review.

PMID:
23643400
2.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007477. doi: 10.1002/14651858.CD007477.pub2. Review.

PMID:
20687088
3.

Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.

Marsella M, Borgna-Pignatti C.

Hematol Oncol Clin North Am. 2014 Aug;28(4):703-27, vi. doi: 10.1016/j.hoc.2014.04.004. Review.

PMID:
25064709
4.

Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.

Puliyel M, Sposto R, Berdoukas VA, Hofstra TC, Nord A, Carson S, Wood J, Coates TD.

Am J Hematol. 2014 Apr;89(4):391-4. doi: 10.1002/ajh.23650. Epub 2014 Feb 28.

5.

Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.

Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.

Eur J Haematol. 2010 Jan 1;84(1):72-8. doi: 10.1111/j.1600-0609.2009.01342.x.

PMID:
19732137
6.

Current approach to iron chelation in children.

Aydinok Y, Kattamis A, Viprakasit V.

Br J Haematol. 2014 Jun;165(6):745-55. doi: 10.1111/bjh.12825. Epub 2014 Mar 20. Review.

PMID:
24646011
7.

Objectives and mechanism of iron chelation therapy.

Hershko C, Link G, Konijn AM, Cabantchik ZI.

Ann N Y Acad Sci. 2005;1054:124-35. Review.

PMID:
16339658
8.

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.

Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.

Am J Hematol. 2008 Apr;83(4):263-70.

9.

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.

Ann Hematol. 2008 Jul;87(7):545-50. doi: 10.1007/s00277-008-0471-2. Epub 2008 Mar 20.

PMID:
18351337
10.

No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia.

Ghoti H, Goitein O, Koren A, Levin C, Kushnir T, Rachmilewitz E, Konen E.

Eur J Haematol. 2010 Jan 1;84(1):59-63. doi: 10.1111/j.1600-0609.2009.01355.x. Epub 2009 Sep 29.

PMID:
19793250
11.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004450. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD004450.

PMID:
16235363
12.

Pharmacotherapy of iron overload in thalassaemic patients.

Ceci A, Felisi M, De Sanctis V, De Mattia D.

Expert Opin Pharmacother. 2003 Oct;4(10):1763-74. Review.

PMID:
14521486
13.

Iron overload in patients with myelodysplastic syndromes.

Jensen PD.

Curr Hematol Malig Rep. 2007 Feb;2(1):13-21. doi: 10.1007/s11899-007-0003-5. Review.

PMID:
20425384
14.

Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.

Ho PJ, Tay L, Lindeman R, Catley L, Bowden DK.

Intern Med J. 2011 Jul;41(7):516-24. doi: 10.1111/j.1445-5994.2011.02527.x. Review.

PMID:
21615659
15.

MRI and iron-overload cardiomyopathy in thalassaemia.

Pennell D.

Circulation. 2006 Mar 21;113(11):f43-4. No abstract available.

16.

Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.

Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE; SWiTCH Study Investigators.

Am J Hematol. 2012 Feb;87(2):221-3. doi: 10.1002/ajh.22228. Epub 2011 Nov 25.

17.

T2* magnetic resonance and myocardial iron in thalassemia.

Pennell DJ.

Ann N Y Acad Sci. 2005;1054:373-8. Review.

PMID:
16339685
18.

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.

Ann Hematol. 2013 Jan;92(2):211-9. doi: 10.1007/s00277-012-1588-x. Epub 2012 Oct 21.

19.

Cardiac iron across different transfusion-dependent diseases.

Wood JC.

Blood Rev. 2008 Dec;22 Suppl 2:S14-21. doi: 10.1016/S0268-960X(08)70004-3. Review.

20.

Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.

Badawy SM, Liem RI, Rigsby CK, Labotka RJ, DeFreitas RA, Thompson AA.

Br J Haematol. 2016 Nov;175(4):705-713. doi: 10.1111/bjh.14277. Epub 2016 Aug 10.

PMID:
27507431

Supplemental Content

Support Center